Metformin reverses mesenchymal phenotype of primary breast cancer cells through STAT3/NF-κB pathways.
José Esparza-LópezJuan Francisco Alvarado-MuñozElizabeth Escobar-ArriagaAlfredo Ulloa-AguirreMaría J Ibarra-SánchezPublished in: BMC cancer (2019)
These results suggest that MTF inhibits IL-6-induced EMT, cell proliferation, and migration of primary breast cancer cells by preventing the activation of STAT3 and NF-κB. STAT3 inactivation occurs through AMPK, but not NF-κB.